Human somatic cell knockouts reveal determinants of sensitivity and resistance to proteasome inhibitor PS-341.
Lee
Carolyn
C
Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA.
Waldman
Todd
T
D000970:Antineoplastic Agents / Q000494:pharmacology; D001897:Boronic Acids / Q000494:pharmacology*; D000069286:Bortezomib; D045744:Cell Line, Tumor; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins / Q000172:deficiency / Q000235:genetics; D003546:Cysteine Endopeptidases / Q000378:metabolism; D004351:Drug Resistance / Q000235:genetics*; D004361:Drug Tolerance / Q000235:genetics*; D018390:Gene Targeting; D045325:HCT116 Cells; D006801:Humans; D009097:Multienzyme Complexes / Q000378:metabolism; D011480:Protease Inhibitors / Q000494:pharmacology*; D046988:Proteasome Endopeptidase Complex; D011518:Proto-Oncogene Proteins / Q000172:deficiency / Q000235:genetics; D019253:Proto-Oncogene Proteins c-bcl-2; D011719:Pyrazines / Q000494:pharmacology*; D012680:Sensitivity and Specificity; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism; D025801:Ubiquitin / Q000378:metabolism; D051028:bcl-2-Associated X Protein
D000970:Antineoplastic Agents; D001897:Boronic Acids; C493956:CDKN1A protein, human; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins; D009097:Multienzyme Complexes; D011480:Protease Inhibitors; D011518:Proto-Oncogene Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D011719:Pyrazines; D016159:Tumor Suppressor Protein p53; D025801:Ubiquitin; D051028:bcl-2-Associated X Protein; D000069286:Bortezomib; D003546:Cysteine Endopeptidases; D046988:Proteasome Endopeptidase Complex